[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-384003-105":59,"doc-detail-384003-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","changes-in-the-number-of-gastrointestinal-cancers-and-stage-at-diagnosis-with-covid-19-pandemic-in-japan-a-multicenter-cohort-study","Changes in the Number of Gastrointestinal Cancers and Stage at Diagnosis with COVID-19 Pandemic in Japan - A Multicenter Cohort Study","","Retrospective cohort research assessed how the COVID-19 pandemic influenced gastrointestinal cancer diagnoses in Japan using hospital-based cancer registry data from two tertiary centers. Comparisons covered three time windows: pre-COVID-19 (Jan 2017–Feb 2020), mid-pandemic (Mar–Dec 2020, phase 1), and transition to the “new normal” (Jan–Dec 2021, phase 2), totaling 6453 patients. Colorectal cancer Stage 0–II declined in phase 1 and rose in phase 2; overall counts returned to pre-pandemic levels. Gastric cancer Stage I decreased further in phase 2, remained below pre-pandemic levels, and screening detection increased for colorectal but stayed low for gastric cancers. Stage III colorectal and gastric cases increased, suggesting potential diagnostic-stage progression.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/changes-in-the-number-of-gastrointestinal-cancers-and-stage-at-diagnosis-with-covid-19-pandemic-in-japan-a-multicenter-cohort-study/384003/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/changes-in-the-number-of-gastrointestinal-cancers-and-stage-at-diagnosis-with-covid-19-pandemic-in-japan-a-multicenter-cohort-study/384003.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How were the study periods defined for comparing cancer diagnoses during COVID-19?","Question",{"text":113,"@type":114},"The study compared pre-COVID-19 (Jan 2017–Feb 2020), mid-pandemic (Mar–Dec 2020, phase 1), and the transition to the “new normal” (Jan–Dec 2021, phase 2). Monthly counts were aggregated for multiple gastrointestinal cancer types.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What happened to colorectal cancer patient numbers and early-stage disease across the phases?",{"text":118,"@type":114},"Colorectal Stage 0–II decreased significantly in phase 1 and increased in phase 2. The overall number of colorectal cancer patients returned to pre-COVID-19 levels.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the key findings for gastric cancer regarding stage distribution and screening detection?",{"text":122,"@type":114},"Gastric cancer Stage I patients decreased significantly in phase 2, remaining fewer than pre-COVID-19 levels. During phase 2, screening detection increased for colorectal cancer but gastric cancer detection remained considerably lower, alongside an increase in Stage III cases.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},384003,1790295403,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","cancers   \nArticle  \nChanges in the Number of Gastrointestinal Cancers and Stage at Diagnosis with COVID-19 Pandemic in Japan: A Multicenter Cohort Study  \nKento Kuzuu 1, Noboru Misawa 1, Keiichi Ashikari 1, Shigeki Tamura 1, Shingo Kato 1, Kunihiro Hosono 1, Masato Yoneda 1, Takashi Nonaka 2, Shozo Matsushima 2, Tatsuji Komatsu 2, Atsushi Nakajima 1 and Takuma Higurashi 1, *  \nCitation: Kuzuu, K.; Misawa, N.; Ashikari, K.; Tamura, S.; Kato, S.; Hosono, K.; Yoneda, M.; Nonaka, T.; Matsushima, S.; Komatsu, T.; et al. Changes in the Number of Gastrointestinal Cancers and Stage at Diagnosis with COVID-19 Pandemic in Japan: A Multicenter Cohort Study.  \nCancers 2023, 15, 4410. [https://](https://)[ ](https://)[doi.org/10.3390/cancers15174410](doi.org/10.3390/cancers15174410)  \nAcademic Editor: Gabriella D'Orazi  \nReceived: 9 July 2023  \nRevised: 13 August 2023  \nAccepted: 1 September 2023  \nPublished: 4 September 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan; [kentokuzuu@yahoo.co.jp](kentokuzuu@yahoo.co.jp) (K.K.); [nobomisa@yokohama-cu.ac.jp](nobomisa@yokohama-cu.ac.jp) (N.M.); [ashikari@yokohama-cu.ac.jp](ashikari@yokohama-cu.ac.jp) (K.A.); [shigeki4321@gmail.com](shigeki4321@gmail.com) (S.T.); [shin800m@yokohama-cu.ac.jp](shin800m@yokohama-cu.ac.jp) (S.K.); [hiro1017@yokohama-cu.ac.jp](hiro1017@yokohama-cu.ac.jp) (K.H.); [yoneda@yokohama-cu.ac.jp](yoneda@yokohama-cu.ac.jp) (M.Y.); [nrk20799@nifty.com](nrk20799@nifty.com) (A.N.)  \n2 National Hospital Organization Yokohama Medical Center, 3-60-2 Harazyuku, Totuka-ku, Yokohama 245-8575, Japan; [nonaka_taka@yahoo.co.jp](nonaka_taka@yahoo.co.jp) (T.N.); [matsushima.shozo.bu@mail.hosp.go.jp](matsushima.shozo.bu@mail.hosp.go.jp) (S.M.); [komatsu.tastuji.je@outlook.jp](komatsu.tastuji.je@outlook.jp) (T.K.)  \n* Correspondence: [takuma_h@yokohama-cu.ac.jp](takuma_h@yokohama-cu.ac.jp); Tel.: +81-45-787-2640  \nSimple Summary: The number of gastrointestinal cancer patients declined during the COVID-19 pandemic. In Japan, the number of early-stage gastric and colorectal cancer patients decreased significantly. However, how gastrointestinal cancers have changed with the shift to the “new normal”remains unknown. Herein, we compared the number of patients, stage at diagnosis, and detection process of the different gastrointestinal cancers in Japan across three periods: pre-COVID-19, Midst of COVID-19 pandemic, and during the transitional period to the “new normal”. The number of colorectal cancer patients decreased in the early phase of the COVID-19 pandemic. It then increased with the shift to the “new normal”, no longer differing from pre-COVID-19 levels. However, gastric cancer patients remained significantly fewer in the “new normal” period than in the pre-COVID-19 period, especially Stage I patients and patients detected through screening. Thus, people with undetected gastric cancer may not be receiving optimal screening, implying a negative prognostication for the near future.  \nAbstract: This retrospective cohort study compared the number of newly diagnosed patients, stage at diagnosis, and detection process of gastrointestinal cancers based on hospital-based cancer registry data at two tertiary Japanese hospitals. The pre-COVID-19 period was from January 2017 to February 2020, with phase 1 (midst of COVID-19 pandemic) from March to December 2020 and phase 2 (the transition period to the “new normal”) from January to December 2021 . Each month, the number of patients diagnosed with esophageal, gastric, colorectal, pancreatic, liver,","cbCaip2wrMLPflMb","https://ap.wps.com/l/cbCaip2wrMLPflMb","pdf",292540,14,"English","# Introduction\n## Study design and periods\n## Outcomes by cancer type and stage\n## Detection process and screening patterns\n## Interpretation and implications","[{\"question\":\"How were the study periods defined for comparing cancer diagnoses during COVID-19?\",\"answer\":\"The study compared pre-COVID-19 (Jan 2017–Feb 2020), mid-pandemic (Mar–Dec 2020, phase 1), and the transition to the “new normal” (Jan–Dec 2021, phase 2). Monthly counts were aggregated for multiple gastrointestinal cancer types.\"},{\"question\":\"What happened to colorectal cancer patient numbers and early-stage disease across the phases?\",\"answer\":\"Colorectal Stage 0–II decreased significantly in phase 1 and increased in phase 2. The overall number of colorectal cancer patients returned to pre-COVID-19 levels.\"},{\"question\":\"What were the key findings for gastric cancer regarding stage distribution and screening detection?\",\"answer\":\"Gastric cancer Stage I patients decreased significantly in phase 2, remaining fewer than pre-COVID-19 levels. During phase 2, screening detection increased for colorectal cancer but gastric cancer detection remained considerably lower, alongside an increase in Stage III cases.\"}]","Changes in the Number of Gastrointestinal Cancers and Stage at Diagnosis with COVID-19 Pandemic in Japan - A Multicenter Cohort Study | PDF",1790260681,35]